Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?

Group 1 - Amneal Pharmaceuticals (AMRX) has outperformed the Medical sector with a year-to-date return of approximately 41.2%, compared to the sector's average return of 8.1% [2] - The Zacks Consensus Estimate for AMRX's full-year earnings has increased by 0.6% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [2] - Amneal Pharmaceuticals holds a Zacks Rank of 1 (Strong Buy), suggesting a favorable investment outlook [1] Group 2 - Amneal Pharmaceuticals is part of the Medical - Drugs industry, which consists of 171 companies and currently ranks 89 in the Zacks Industry Rank, while the industry has seen an average loss of 2.9% this year [3] - Astrazeneca (AZN), another outperforming Medical stock, has returned 14.9% year-to-date and has a Zacks Rank of 2 (Buy) [2][3] - The Large Cap Pharmaceuticals industry, to which Astrazeneca belongs, is ranked 66 and has experienced a gain of 21.2% this year [3]